Albert David Limited (NSE: ALBERTDAVD.NS) Stock Competitors & Peer Comparison

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SUNPHARMA.BO has a market cap of 4.7T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SUNPHARMA.BO trades at ₹1,949.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SUNPHARMA.BO's P/E ratio is 38.22. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SUNPHARMA.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SUNPHARMA.NS has a market cap of 4.7T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SUNPHARMA.NS trades at ₹1,945.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SUNPHARMA.NS's P/E ratio is 37.78. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SUNPHARMA.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, DIVISLAB.BO has a market cap of 2.2T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while DIVISLAB.BO trades at ₹8,248.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas DIVISLAB.BO's P/E ratio is 74.86. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to DIVISLAB.BO's ROE of +0.18%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check DIVISLAB.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, DIVISLAB.NS has a market cap of 2.2T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while DIVISLAB.NS trades at ₹8,275.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas DIVISLAB.NS's P/E ratio is 75.12. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to DIVISLAB.NS's ROE of +0.18%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check DIVISLAB.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, TORNTPHARM.BO has a market cap of 1.9T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while TORNTPHARM.BO trades at ₹4,952.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas TORNTPHARM.BO's P/E ratio is 75.14. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to TORNTPHARM.BO's ROE of +0.20%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to TORNTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check TORNTPHARM.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, TORNTPHARM.NS has a market cap of 1.9T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while TORNTPHARM.NS trades at ₹4,924.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas TORNTPHARM.NS's P/E ratio is 73.78. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to TORNTPHARM.NS's ROE of +0.20%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to TORNTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check TORNTPHARM.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, CIPLA.NS has a market cap of 1.2T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while CIPLA.NS trades at ₹1,463.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas CIPLA.NS's P/E ratio is 30.50. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to CIPLA.NS's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to CIPLA.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check CIPLA.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ZYDUSLIFE.BO trades at ₹1,115.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ZYDUSLIFE.BO's P/E ratio is 23.26. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ZYDUSLIFE.BO's ROE of +0.19%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ZYDUSLIFE.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ZYDUSLIFE.NS trades at ₹1,114.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ZYDUSLIFE.NS's P/E ratio is 23.15. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ZYDUSLIFE.NS's ROE of +0.19%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ZYDUSLIFE.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while LUPIN.NS trades at ₹2,363.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas LUPIN.NS's P/E ratio is 18.56. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check LUPIN.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while LUPIN.BO trades at ₹2,360.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas LUPIN.BO's P/E ratio is 18.52. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check LUPIN.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while MANKIND.NS trades at ₹2,456.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas MANKIND.NS's P/E ratio is 49.72. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to MANKIND.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check MANKIND.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while MANKIND.BO trades at ₹2,439.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas MANKIND.BO's P/E ratio is 49.69. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to MANKIND.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check MANKIND.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, LAURUSLABS.BO has a market cap of 1T. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while LAURUSLABS.BO trades at ₹1,855.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas LAURUSLABS.BO's P/E ratio is 112.22. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to LAURUSLABS.BO's ROE of +0.21%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to LAURUSLABS.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check LAURUSLABS.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, LAURUSLABS.NS has a market cap of 996.4B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while LAURUSLABS.NS trades at ₹1,844.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas LAURUSLABS.NS's P/E ratio is 112.05. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to LAURUSLABS.NS's ROE of +0.21%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to LAURUSLABS.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check LAURUSLABS.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, DRREDDY.BO has a market cap of 984.7B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while DRREDDY.BO trades at ₹1,172.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas DRREDDY.BO's P/E ratio is 22.79. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to DRREDDY.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check DRREDDY.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, DRREDDY.NS has a market cap of 976.3B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while DRREDDY.NS trades at ₹1,172.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas DRREDDY.NS's P/E ratio is 22.79. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to DRREDDY.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check DRREDDY.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, AUROPHARMA.BO has a market cap of 955.3B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while AUROPHARMA.BO trades at ₹1,661.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas AUROPHARMA.BO's P/E ratio is 25.95. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check AUROPHARMA.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, AUROPHARMA.NS has a market cap of 954B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while AUROPHARMA.NS trades at ₹1,658.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas AUROPHARMA.NS's P/E ratio is 25.91. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check AUROPHARMA.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ALKEM.BO has a market cap of 672.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ALKEM.BO trades at ₹5,630.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ALKEM.BO's P/E ratio is 29.24. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ALKEM.BO's ROE of +0.17%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ALKEM.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ALKEM.NS has a market cap of 672B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ALKEM.NS trades at ₹5,620.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ALKEM.NS's P/E ratio is 34.60. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ALKEM.NS's ROE of +0.17%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ALKEM.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GLENMARK.BO has a market cap of 660.6B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GLENMARK.BO trades at ₹2,287.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GLENMARK.BO's P/E ratio is 47.41. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GLENMARK.BO's ROE of +0.19%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GLENMARK.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GLENMARK.NS has a market cap of 643.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GLENMARK.NS trades at ₹2,279.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GLENMARK.NS's P/E ratio is 37.36. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GLENMARK.NS's ROE of +0.19%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to GLENMARK.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GLENMARK.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, IPCALAB.BO has a market cap of 443.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while IPCALAB.BO trades at ₹1,736.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas IPCALAB.BO's P/E ratio is 48.43. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to IPCALAB.BO's ROE of +0.14%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check IPCALAB.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, IPCALAB.NS has a market cap of 440.4B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while IPCALAB.NS trades at ₹1,735.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas IPCALAB.NS's P/E ratio is 37.52. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to IPCALAB.NS's ROE of +0.14%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check IPCALAB.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, AJANTPHARM.NS has a market cap of 435.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while AJANTPHARM.NS trades at ₹3,489.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas AJANTPHARM.NS's P/E ratio is 41.32. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to AJANTPHARM.NS's ROE of +0.27%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to AJANTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check AJANTPHARM.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, AJANTPHARM.BO has a market cap of 435.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while AJANTPHARM.BO trades at ₹3,488.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas AJANTPHARM.BO's P/E ratio is 41.31. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to AJANTPHARM.BO's ROE of +0.27%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to AJANTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check AJANTPHARM.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GLAND.NS has a market cap of 429.1B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GLAND.NS trades at ₹2,601.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GLAND.NS's P/E ratio is 41.67. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GLAND.NS's ROE of +0.11%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to GLAND.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GLAND.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GLAND.BO has a market cap of 428.7B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GLAND.BO trades at ₹2,600.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GLAND.BO's P/E ratio is 41.67. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GLAND.BO's ROE of +0.11%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to GLAND.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GLAND.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SUVENPHAR.NS's ROE of +0.05%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SUVENPHAR.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SUVENPHAR.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SUVENPHAR.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SUVENPHAR.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while JBCHEPHARM.NS trades at ₹2,416.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to JBCHEPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check JBCHEPHARM.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, EMCURE.NS has a market cap of 375.3B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while EMCURE.NS trades at ₹1,978.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas EMCURE.NS's P/E ratio is 74.66. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to EMCURE.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check EMCURE.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, WOCKPHARMA.BO has a market cap of 328.1B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while WOCKPHARMA.BO trades at ₹2,020.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas WOCKPHARMA.BO's P/E ratio is 154.13. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to WOCKPHARMA.BO's ROE of +0.04%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to WOCKPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check WOCKPHARMA.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, NEULANDLAB.BO has a market cap of 293.7B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while NEULANDLAB.BO trades at ₹22,843.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas NEULANDLAB.BO's P/E ratio is 58.07. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to NEULANDLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check NEULANDLAB.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, NEULANDLAB.NS has a market cap of 293.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while NEULANDLAB.NS trades at ₹22,855.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas NEULANDLAB.NS's P/E ratio is 57.94. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to NEULANDLAB.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check NEULANDLAB.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, PPLPHARMA.NS has a market cap of 277.7B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while PPLPHARMA.NS trades at ₹209.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas PPLPHARMA.NS's P/E ratio is -178.93. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to PPLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check PPLPHARMA.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, PPLPHARMA.BO has a market cap of 276.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while PPLPHARMA.BO trades at ₹209.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas PPLPHARMA.BO's P/E ratio is -178.80. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to PPLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check PPLPHARMA.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to PEL.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check PEL.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GRANULES.BO has a market cap of 217.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GRANULES.BO trades at ₹872.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GRANULES.BO's P/E ratio is 35.11. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GRANULES.BO's ROE of +0.16%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to GRANULES.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GRANULES.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GRANULES.NS has a market cap of 216.5B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GRANULES.NS trades at ₹873.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GRANULES.NS's P/E ratio is 35.18. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GRANULES.NS's ROE of +0.16%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to GRANULES.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GRANULES.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ASTRAZEN.BO has a market cap of 204.8B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ASTRAZEN.BO trades at ₹8,188.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ASTRAZEN.BO's P/E ratio is 109.16. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ASTRAZEN.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ASTRAZEN.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ASTRAZEN.NS has a market cap of 204.8B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ASTRAZEN.NS trades at ₹8,191.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ASTRAZEN.NS's P/E ratio is 109.20. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ASTRAZEN.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ASTRAZEN.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, CAPLIPOINT.BO has a market cap of 195.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while CAPLIPOINT.BO trades at ₹2,577.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas CAPLIPOINT.BO's P/E ratio is 34.27. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to CAPLIPOINT.BO's ROE of +0.20%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to CAPLIPOINT.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check CAPLIPOINT.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, CAPLIPOINT.NS has a market cap of 195.7B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while CAPLIPOINT.NS trades at ₹2,574.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas CAPLIPOINT.NS's P/E ratio is 30.25. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to CAPLIPOINT.NS's ROE of +0.20%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to CAPLIPOINT.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check CAPLIPOINT.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ERIS.BO has a market cap of 191.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ERIS.BO trades at ₹1,384.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ERIS.BO's P/E ratio is 44.88. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ERIS.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ERIS.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ERIS.NS has a market cap of 191.6B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ERIS.NS trades at ₹1,382.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ERIS.NS's P/E ratio is 39.11. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ERIS.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ERIS.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, COHANCE.NS has a market cap of 170.5B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while COHANCE.NS trades at ₹445.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas COHANCE.NS's P/E ratio is 134.80. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to COHANCE.NS's ROE of +0.03%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to COHANCE.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check COHANCE.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, COHANCE.BO has a market cap of 170.1B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while COHANCE.BO trades at ₹445.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas COHANCE.BO's P/E ratio is 140.82. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to COHANCE.BO's ROE of +0.03%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to COHANCE.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check COHANCE.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, NATCOPHARM.BO has a market cap of 164.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while NATCOPHARM.BO trades at ₹917.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas NATCOPHARM.BO's P/E ratio is 12.37. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check NATCOPHARM.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, NATCOPHARM.NS has a market cap of 164.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while NATCOPHARM.NS trades at ₹916.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas NATCOPHARM.NS's P/E ratio is 12.39. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check NATCOPHARM.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ALIVUS.NS has a market cap of 163.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ALIVUS.NS trades at ₹1,329.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ALIVUS.NS's P/E ratio is 49.53. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ALIVUS.NS's ROE of +0.20%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ALIVUS.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ALIVUS.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, APLLTD.NS has a market cap of 163.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while APLLTD.NS trades at ₹830.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas APLLTD.NS's P/E ratio is 21.73. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check APLLTD.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, APLLTD.BO has a market cap of 163B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while APLLTD.BO trades at ₹829.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas APLLTD.BO's P/E ratio is 21.72. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check APLLTD.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ALIVUS.BO has a market cap of 163B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ALIVUS.BO trades at ₹1,328.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ALIVUS.BO's P/E ratio is 29.55. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ALIVUS.BO's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ALIVUS.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ALIVUS.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SHILPAMED.NS has a market cap of 148.6B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SHILPAMED.NS trades at ₹759.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SHILPAMED.NS's P/E ratio is 52.11. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SHILPAMED.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SHILPAMED.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, JUBLPHARMA.BO has a market cap of 147.8B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while JUBLPHARMA.BO trades at ₹931.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas JUBLPHARMA.BO's P/E ratio is 34.77. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to JUBLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check JUBLPHARMA.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, JUBLPHARMA.NS has a market cap of 147.6B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while JUBLPHARMA.NS trades at ₹932.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas JUBLPHARMA.NS's P/E ratio is 34.71. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to JUBLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check JUBLPHARMA.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to GLS.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GLS.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GLS.BO's ROE of +0.21%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to GLS.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GLS.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, VIYASH.NS has a market cap of 120.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while VIYASH.NS trades at ₹277.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas VIYASH.NS's P/E ratio is 86.02. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to VIYASH.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check VIYASH.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to CAPPL.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check CAPPL.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SUDEEPPHRM.NS has a market cap of 108.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SUDEEPPHRM.NS trades at ₹957.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SUDEEPPHRM.NS's P/E ratio is 110.70. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SUDEEPPHRM.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SUDEEPPHRM.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, AKUMS.NS has a market cap of 106.8B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while AKUMS.NS trades at ₹697.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas AKUMS.NS's P/E ratio is 55.84. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to AKUMS.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check AKUMS.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, PGHL.BO has a market cap of 102.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while PGHL.BO trades at ₹6,149.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas PGHL.BO's P/E ratio is 34.08. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to PGHL.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check PGHL.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, PGHL.NS has a market cap of 102B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while PGHL.NS trades at ₹6,144.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas PGHL.NS's P/E ratio is 31.21. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to PGHL.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check PGHL.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, STAR.BO has a market cap of 92.5B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while STAR.BO trades at ₹1,007.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas STAR.BO's P/E ratio is 16.70. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to STAR.BO's ROE of +0.22%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to STAR.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check STAR.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, STAR.NS has a market cap of 92.5B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while STAR.NS trades at ₹1,003.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas STAR.NS's P/E ratio is 16.65. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to STAR.NS's ROE of +0.22%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to STAR.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check STAR.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SHILPAMED.BO has a market cap of 74.3B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SHILPAMED.BO trades at ₹759.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SHILPAMED.BO's P/E ratio is 54.06. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SHILPAMED.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SHILPAMED.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SUVEN.NS has a market cap of 72.6B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SUVEN.NS trades at ₹318.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SUVEN.NS's P/E ratio is -26.40. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SUVEN.NS's ROE of -0.87%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SUVEN.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SUVEN.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SUVEN.BO has a market cap of 71.7B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SUVEN.BO trades at ₹318.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SUVEN.BO's P/E ratio is -25.64. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SUVEN.BO's ROE of -0.87%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SUVEN.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SUVEN.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SPARC.NS has a market cap of 69.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SPARC.NS trades at ₹213.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SPARC.NS's P/E ratio is 4.46. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SPARC.NS's ROE of +14.36%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SPARC.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SPARC.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SPARC.BO has a market cap of 68.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SPARC.BO trades at ₹211.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SPARC.BO's P/E ratio is 4.45. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SPARC.BO's ROE of +14.36%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SPARC.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SPARC.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, AARTIPHARM.NS has a market cap of 62.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while AARTIPHARM.NS trades at ₹685.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas AARTIPHARM.NS's P/E ratio is 23.71. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to AARTIPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check AARTIPHARM.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, AARTIPHARM.BO has a market cap of 61.8B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while AARTIPHARM.BO trades at ₹684.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas AARTIPHARM.BO's P/E ratio is 33.04. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to AARTIPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check AARTIPHARM.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, FDC.NS has a market cap of 60.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while FDC.NS trades at ₹369.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas FDC.NS's P/E ratio is 21.39. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to FDC.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check FDC.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, INNOVACAP.NS has a market cap of 54B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while INNOVACAP.NS trades at ₹944.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas INNOVACAP.NS's P/E ratio is 44.41. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to INNOVACAP.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check INNOVACAP.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ORCHPHARMA.BO has a market cap of 50.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ORCHPHARMA.BO trades at ₹1,004.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ORCHPHARMA.BO's P/E ratio is 78.24. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ORCHPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ORCHPHARMA.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, BLISSGVS.BO has a market cap of 50.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while BLISSGVS.BO trades at ₹477.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas BLISSGVS.BO's P/E ratio is 39.59. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to BLISSGVS.BO's ROE of +0.11%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to BLISSGVS.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check BLISSGVS.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, ORCHPHARMA.NS has a market cap of 50.8B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while ORCHPHARMA.NS trades at ₹1,001.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas ORCHPHARMA.NS's P/E ratio is 161.59. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to ORCHPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check ORCHPHARMA.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, BLISSGVS.NS has a market cap of 50.6B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while BLISSGVS.NS trades at ₹477.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas BLISSGVS.NS's P/E ratio is 39.63. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to BLISSGVS.NS's ROE of +0.11%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to BLISSGVS.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check BLISSGVS.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SEQUENT.NS's ROE of +0.09%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SEQUENT.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SEQUENT.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SEQUENT.BO's ROE of +0.09%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SEQUENT.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SEQUENT.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, IOLCP.NS has a market cap of 49.3B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while IOLCP.NS trades at ₹167.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas IOLCP.NS's P/E ratio is 33.04. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to IOLCP.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check IOLCP.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, IOLCP.BO has a market cap of 49.3B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while IOLCP.BO trades at ₹167.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas IOLCP.BO's P/E ratio is 32.90. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to IOLCP.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check IOLCP.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, RPGLIFE.BO has a market cap of 44.3B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while RPGLIFE.BO trades at ₹2,658.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas RPGLIFE.BO's P/E ratio is 38.17. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to RPGLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check RPGLIFE.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, RPGLIFE.NS has a market cap of 44B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while RPGLIFE.NS trades at ₹2,661.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas RPGLIFE.NS's P/E ratio is 38.22. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to RPGLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check RPGLIFE.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, MOREPENLAB.NS has a market cap of 44B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while MOREPENLAB.NS trades at ₹80.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas MOREPENLAB.NS's P/E ratio is 42.69. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to MOREPENLAB.NS's ROE of +0.12%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to MOREPENLAB.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check MOREPENLAB.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, MOREPENLAB.BO has a market cap of 43.9B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while MOREPENLAB.BO trades at ₹80.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas MOREPENLAB.BO's P/E ratio is 46.31. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to MOREPENLAB.BO's ROE of +0.12%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to MOREPENLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check MOREPENLAB.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GUFICBIO.BO has a market cap of 42.3B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GUFICBIO.BO trades at ₹422.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GUFICBIO.BO's P/E ratio is 65.98. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to GUFICBIO.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GUFICBIO.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GUFICBIO.NS has a market cap of 42.3B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GUFICBIO.NS trades at ₹421.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GUFICBIO.NS's P/E ratio is 65.84. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to GUFICBIO.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GUFICBIO.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, NOVARTIND.BO has a market cap of 39.7B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while NOVARTIND.BO trades at ₹1,609.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas NOVARTIND.BO's P/E ratio is 41.89. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to NOVARTIND.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check NOVARTIND.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, NOVARTIND.NS has a market cap of 39.7B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while NOVARTIND.NS trades at ₹1,609.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas NOVARTIND.NS's P/E ratio is 41.88. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to NOVARTIND.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check NOVARTIND.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, GUJTHEM.NS has a market cap of 38.8B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while GUJTHEM.NS trades at ₹355.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas GUJTHEM.NS's P/E ratio is 82.78. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, ALBERTDAVD.NS is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check GUJTHEM.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, AARTIDRUGS.BO has a market cap of 38B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while AARTIDRUGS.BO trades at ₹417.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas AARTIDRUGS.BO's P/E ratio is 19.59. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to AARTIDRUGS.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check AARTIDRUGS.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, AARTIDRUGS.NS has a market cap of 38B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while AARTIDRUGS.NS trades at ₹416.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas AARTIDRUGS.NS's P/E ratio is 19.59. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to AARTIDRUGS.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check AARTIDRUGS.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, UNICHEMLAB.NS has a market cap of 34.5B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while UNICHEMLAB.NS trades at ₹489.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas UNICHEMLAB.NS's P/E ratio is 13.64. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to UNICHEMLAB.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check UNICHEMLAB.NS's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, UNICHEMLAB.BO has a market cap of 34.4B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while UNICHEMLAB.BO trades at ₹488.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas UNICHEMLAB.BO's P/E ratio is 13.59. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to UNICHEMLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check UNICHEMLAB.BO's competition here

Albert David Limited (NSE: ALBERTDAVD.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBERTDAVD.NS stands at 4.7B. In comparison, SOLARA.NS has a market cap of 24.2B. Regarding current trading prices, ALBERTDAVD.NS is priced at ₹822.85 on the NSE, while SOLARA.NS trades at ₹502.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBERTDAVD.NS currently has a P/E ratio of -314.06, whereas SOLARA.NS's P/E ratio is 285.57. In terms of profitability, ALBERTDAVD.NS's ROE is -0.00%, compared to SOLARA.NS's ROE of -0.00%. Regarding short-term risk, ALBERTDAVD.NS is more volatile compared to SOLARA.NS. This indicates higher risk in terms of short-term price fluctuations for ALBERTDAVD.NS.Check SOLARA.NS's competition here